In some studies, treatment with empagliflozin and canagliflozin reduced interferon-λ, TNFα, and IL-6 serum levels, while with dapagliflozin—also CRP concentration with a parallel increase of adiponectin in T2D patients reviewed in [135]. The gene discussed is IL6; the disease is type 2 diabetes mellitus.